AstraZeneca prices EUR 1.4bn eurobond offering

AstraZeneca announced on Tuesday that its wholly owned subsidiary, AstraZeneca Finance, priced a €1.4bn eurobond offering on 29 July.

The FTSE 100 pharmaceutical giant said the offering, expected to close on 5 August, consists of two tranches of fixed-rate notes.

It said the first tranche included €650m of notes with a coupon of 3.121%, maturing on 5 August 2030.

The second tranche consisted of €750m of notes with a coupon of 3.278%, maturing on 5 August 2033.

AstraZeneca said it fully and unconditionally guaranteed the notes.

The net proceeds from the offering would be used for general corporate purposes.

BNP Paribas, Goldman Sachs International, Morgan Stanley and Société Générale served as joint book-running managers for the transaction.

The firm said the notes were being issued under its $10bn EMTN programme, and would be listed on the FCA’s Official List, trading on the London Stock Exchange's main market.

They had not been registered under the US Securities Act, and as such could not be offered or sold in the United States without registration or an applicable exemption.

At 1137 BST, shares in AstraZeneca were down 0.87% at 12m256p.

Reporting by Josh White for Sharecast.com.